Wegovy Cost with Insurance: Real Prices & Coverage in 2026

The amount a patient pays for Wegovy depends on the exact presentation, insurance pathway, formulary, authorization rules, deductible, quantity and current manufacturer terms. This guide separates plan-specific coverage from cash offers and uses clearly labeled examples where a personal quote is not available.

How Much You'll Pay: Commercial Insurance

Employer and marketplace plans differ in whether they cover Wegovy, which indication they recognize, what tier they use, whether prior authorization applies and how the deductible or coinsurance is calculated. A formulary listing is not a patient-cost quote, and meeting a label or plan criterion does not guarantee approval.

• Check the exact Wegovy presentation, strength, quantity and treated indication.
• Ask whether the plan requires prior authorization, step therapy, renewal documentation or a quantity limit.
• Ask how the fill will apply to the deductible and out-of-pocket maximum.
• Confirm whether the commercial savings offer can be processed; accumulator and copay-maximizer plans make the offer ineligible.

Understanding Your Formulary Tier

A tier is a plan-design category, not a standardized Wegovy price. Some plans use a fixed copay while others use coinsurance against a negotiated allowed amount; a deductible can change the result. Search the plan's current formulary for Wegovy and ask the member-services representative to quote the prescribed presentation rather than relying on a generic tier range.

Prior Authorization: The Real Timeline

When a plan requires prior authorization, the prescriber submits the information requested by that plan. The review may result in approval, denial or a request for additional information. The plan notice controls the timing, renewal requirements and any rule for treatment while the request is pending. Do not assume that a cash fill will later be reimbursed; ask the plan and pharmacy first.

1. Read the plan criteria: Note the covered indication, required documentation, quantity and renewal rules.
2. Coordinate the submission: Give the prescriber the plan's form, deadline and exact denial or request language.
3. Check the decision: Keep the approval, denial or request for information and verify the approved presentation and dates.
4. Plan the fill: Ask the pharmacy for the patient cost under the approved claim before paying cash.

The Novo Nordisk Savings Offer

NovoCare's current Wegovy savings-offer overview and its current terms separate the commercial-insurance offer from self-pay terms outside insurance. For eligible commercially insured patients whose plan covers Wegovy, the display says patients may pay as little as $25, subject to maximum savings of $100 for a one-month fill, $200 for a two-month fill or $300 for a three-month fill. A monthly fill means 28 days for the injection presentation or 30 tablets for the tablet presentation. That display is not a guaranteed patient cost: plan cost-sharing, eligibility and claim processing still control the result.

The commercial offer excludes government prescription coverage such as Medicare, Medicaid, VA and TRICARE. Novo's terms treat FEHB, marketplace and state-employee insurance as commercial rather than government programs for this offer. It is also unavailable when the plan uses an accumulator adjustment or copay maximizer, and the terms prohibit using the savings program in those circumstances. A valid prescription, prescriber ID and FDA-approved labeled indication are required; other coupons generally cannot be combined, apart from the manufacturer's permitted automatic eVoucher. For illustration only, a $250 plan cost share less a maximum $100 one-month savings would leave $150; an applicable $50 savings on a $75 cost share would leave $25. These examples assume eligibility and successful claim processing.

NovoCare also lists a separate self-pay pathway outside insurance. A cash purchase through that pathway is not reimbursed by insurance and does not credit a deductible, out-of-pocket maximum or Part D TrOOP. For eligible new self-pay patients with no offer in the prior 365 days, the current display lists $199 for each of the first two 28-day injection fills of 0.25 mg or 0.5 mg which must be filled by December 31, 2026. The standard injection display is $349 per 28-day fill for 0.25 mg through 2.4 mg and $399 for HD 7.2 mg. Tablet terms are separate: $149 for 1.5 mg, $199 for 4 mg, and $299 for 9 mg or 25 mg per 30-tablet bottle. A prior $149 4 mg tablet offer expired August 31, 2026.

Real-World Cost Breakdown: Tier-by-Tier

These rows show what to verify, not universal tier prices. Replace each placeholder with the plan's written benefit response for the prescribed presentation.

Brand Wegovy vs. Compounded Semaglutide: Cost Comparison

A cash quote for a compound is not a Wegovy price, and an insurer's handling of one product does not establish coverage for the other. Compounded semaglutide is not an FDA-approved generic Wegovy product. The FDA compounding questions and answers explain the distinction between approved products and compounded preparations; they do not support a universal price, quality or coverage promise.

If a compound is discussed, ask which pharmacy prepared it, what the exact product and concentration are, how it is labeled and stored, and what records support the pharmacy's authorization. Cost alone does not establish equivalence, safety or appropriateness. Do not substitute a dose or product without the prescriber's direction.

Medicare: Coverage for Semaglutide

Medicare Wegovy coverage should be analyzed by indication and pathway, not by a blanket statement about type 2 diabetes. The CMS provider information describes the current GLP-1 Bridge criteria at GLP-1 initiation for adults age 18 and older enrolled in a qualifying Part D plan. The relevant BMI is the BMI at initiation: 35 or higher, or 30 or higher with HFpEF, uncontrolled hypertension (over 140 systolic or over 90 diastolic despite two antihypertensive medicines) or CKD stage 3a or higher, or 27 or higher with prediabetes, a prior myocardial infarction or stroke, or symptomatic peripheral artery disease. Prior authorization and an accurate current-and-ongoing structured nutrition and physical-activity attestation apply.

The CMS Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027. An eligible participant pays a $50 monthly copay outside ordinary Part D payment flow for a 28- or 30-day supply. It is not subject to the Part D deductible and does not credit Part D TrOOP, the spending that counts toward the Part D out-of-pocket limit. Extra Help does not reduce this $50 copay, which cannot be placed into the Medicare Prescription Payment Plan. Bridge has no appeals process. If the initial information was incorrect or more information becomes available after a denial, the prescriber may resubmit corrected or additional information; that is different from an ordinary plan appeal.

A prescription for another indication follows the applicable ordinary Part D pathway and plan rules. CMS routes type 2 diabetes, moderate-to-severe obstructive sleep apnea, noncirrhotic MASH with F2-F3 fibrosis and prescriptions for MACE risk reduction (major cardiovascular events) to ordinary Part D rather than Bridge. People with any GLP-1 covered under Part D in CY2026 are not Bridge-eligible; CMS says the relevant 2027 lookback is not yet determined. This describes the coverage pathway, not an indication shared by every GLP-1 product. Medicare's weight-loss-drug page and the member's plan should control the current answer. Coverage for an Ozempic diabetes indication does not make Wegovy a T2D-only product or establish coverage for Wegovy.

Medicaid: State-by-State Variation

Medicaid coverage is state-, product-, indication- and plan-specific. Use the official state Medicaid agency directory or your managed-care plan to check Wegovy coverage, authorization criteria, quantity limits and patient responsibility.

• Ask whether the plan covers the prescribed product for the treated indication.
• Request the current prior-authorization form and renewal criteria.
• Use the denial notice and the state or plan's stated appeal route if coverage is denied.

No Insurance: Cash Prices & Alternatives

Without insurance, compare a current cash quote for the exact Wegovy presentation, dose, quantity and pharmacy. The NovoCare self-pay terms above are separate from insurance and include eligibility and expiry conditions; they are not a universal price for every patient. The current NovoCare patient-assistance product list does not list Wegovy, so a general PAP page should not be presented as free Wegovy access. A discount-card result is a quote for a specified pharmacy, not proof of insurance coverage or an approved generic.

If a compounded product is considered, keep it distinct from Wegovy and from an FDA-approved generic. The FDA's GLP-1 information explains why an unapproved compounded product should not be represented as the approved brand. Verify the exact product in Drugs@FDA or the Orange Book rather than assuming that a listing or marketing phrase means generic approval.

How to Appeal a Denial: What Actually Works

An appeal should answer the reason in the actual denial or explanation of benefits. Start with the plan's written internal-appeal procedure, deadline, submission channel and covered indication. If the notice permits an expedited review, follow that route; urgent care is not a workaround for a routine cost question.

Checklist: What to Ask Your Insurance Company

Use the member-services number on the insurance card and record the date, representative, reference number and exact wording of the answer.

• Is the prescribed Wegovy presentation covered for this indication?
• What tier, deductible, copay or coinsurance applies to this strength and quantity?
• Is prior authorization, step therapy or renewal documentation required?
• What quantity limit and fill window apply?
• How will a cash purchase or manufacturer offer affect deductible and out-of-pocket accumulators?
• Does an accumulator or maximizer provision affect the commercial savings offer?
• What are the internal-appeal deadline and submission route if the claim is denied?
• Which external-review or regulator jurisdiction applies if the plan notice permits it?

Cost Timeline: A Hypothetical First Three Fills

This is an explicitly hypothetical planning budget, not a typical patient result, calendar 90-day fill or individualized titration schedule. It assumes three 28-day injection supplies at $75 each, with four weekly doses per supply; the product, dose, coverage and actual cost must be confirmed separately.

Why Drugs Sit on Different Tiers: The Business Behind It

Plans set tiers through benefit design, negotiated prices, formulary strategy, utilization management and the indication or presentation being covered. A tier can affect cost sharing, but it does not by itself show that a product is covered, medically appropriate or interchangeable with another product.

• Benefit design: A fixed copay, coinsurance and deductible produce different patient costs.
• Negotiated price: The plan's allowed amount is not the manufacturer list price and may not be visible in a public price table.
• Utilization management: Prior authorization, step therapy and quantity limits can apply at any tier.
• Indication and presentation: Coverage for one product, strength or indication does not establish coverage for another.

Brand Wegovy and Semaglutide Products: Different Labels and Costs

Wegovy is an FDA-approved semaglutide product with its own label and presentations. Do not treat the phrase “generic semaglutide” as proof that an FDA-approved generic Wegovy product is available or interchangeable. Verify the exact product in Drugs@FDA or the Orange Book.

• Brand Wegovy: Use the current product label and NovoCare terms for the prescribed presentation.
• Compounded semaglutide: Not an FDA-approved generic; a patient-specific compound raises separate pharmacy, formulation, labeling and evidence questions.
• Other semaglutide products: A different brand, indication, presentation or coverage pathway is not a dose-for-dose substitute.

Discuss any alternative with the prescriber. A lower quote does not establish equivalent indication, dose, quality, coverage or clinical outcome.

Bottom Line

A Wegovy cost estimate is only useful when it names the product presentation, dose, quantity, plan, benefit stage and current manufacturer terms. Commercial terms display a patient price as little as $25 for an eligible covered patient, subject to the current savings caps and claim rules; it is not a universal copay. Medicare Bridge eligibility and ordinary Part D pathways are different, and Medicaid is state-, product-, indication- and plan-specific.

Keep a denial notice, coverage quote and cash quote together. Follow the actual plan appeal route when coverage is denied, and do not treat a compounded product as an FDA-approved generic or an automatic replacement for Wegovy.